Variability in Duration of Outpatient Diuretic Therapy in Bronchopulmonary Dysplasia: A Clinical Experience

ABSTRACT

We describe usual duration of outpatient diuretic therapy and duration of tapering of outpatient diuretics in infants with established bronchopulmonary dysplasia (BPD), and we identify factors associated with duration of diuretic taper. Infants with BPD discharged from the neonatal intensive care unit on diuretic therapy were identified and data were abstracted from clinical databases and medical records. BPD was defined as oxygen dependence at 28 days of life. Infants with chromosomal abnormalities or congenital heart disease and those requiring tracheostomy placement were excluded. Descriptive, univariate, and multivariate analyses were performed. Of 59 patients discharged on diuretic therapy, 10 were also discharged on oxygen. Median (25th, 75th percentiles) duration of outpatient diuretic therapy was 94 (69, 115) days and 30 (14, 84) days for duration of diuretic taper. Duration of therapy and duration of taper were significantly longer in infants discharged on oxygen. In Cox proportional hazards modeling, longer diuretic taper was associated with a higher dose of chlorothiazide at discharge, shorter interval to first outpatient visit, need for rehospitalization, and African-American race. Birth weight, gestational age, and various discharge therapies were not significantly associated with duration of taper after adjusting for these factors. In 58% of all patients, diuretics were tapered or discontinued at the first outpatient visit. This study demonstrated great variability in the duration of diuretic therapy and diuretic taper. Discharge on oxygen was associated with longer duration of diuretic therapy and taper. Active taper is successful in the majority of patients and should be considered in patients with stable BPD.

KEYWORDS

Chronic lung disease - spironolactone - thiazides - infants

REFERENCES

• 1 McCann E M, Lewis K, Deming D D, Donovan M J, Brady J P. Controlled trial of furosemide therapy in infants with chronic lung disease.  J Pediatr. 1985;  106 957-962
• 2 Clark R H, Bloom B T, Spitzer A R, Gerstmann D R. Reported medication use in the neonatal intensive care unit: data from a large national data set.  Pediatrics. 2006;  117 1979-1987
• 3 Brion L P, Primhak R A, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease.  Cochrane Database Syst Rev. 2002;  (1) CD001817
• 4 Van Marter L J. Epidemiology of bronchopulmonary dysplasia.  Semin Fetal Neonatal Med. 2009;  14 358-366
• 5 Madan A, Brozanski B S, Cole C H, Oden N L, Cohen G, Phelps D L. A pulmonary score for assessing the severity of neonatal chronic lung disease.  Pediatrics. 2005;  115 e450-e457
• 6 Hussain N, Kimble C, Pappagallo M. “Stress oximetry”: a useful test for predicting discontinuation of supplemental oxygen in infants with BPD.  Am J Respir Crit Care Med. 2002;  165 A645
• 7 Bancalari E, Wilson-Costello D, Iben S C. Management of infants with bronchopulmonary dysplasia in North America.  Early Hum Dev. 2005;  81 171-179
• 8 Christou H, Brodsky D. Lung injury and bronchopulmonary dysplasia in newborn infants.  J Intensive Care Med. 2005;  20 76-87
• 9 Tin W, Wiswell T E. Adjunctive therapies in chronic lung disease: examining the evidence.  Semin Fetal Neonatal Med. 2008;  13 44-52
• 10 Kao L C, Warburton D, Sargent C W, Platzker A C, Keens T G. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia.  J Pediatr. 1983;  103 624-629
• 11 Kao L C, Warburton D, Cheng M H, Cedeño C, Platzker A C, Keens T G. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial.  Pediatrics. 1984;  74 37-44
• 12 Kao L C, Durand D J, Phillips B L, Nickerson B G. Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia.  J Pediatr. 1987;  111 439-444
• 13 Kao L C, Durand D J, Nickerson B G. Improving pulmonary function does not decrease oxygen consumption in infants with bronchopulmonary dysplasia.  J Pediatr. 1988;  112 616-621
• 14 Engelhardt B, Elliott S, Hazinski T A. Short- and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia.  J Pediatr. 1986;  109 1034-1039
• 15 Kao L C, Durand D J, McCrea R C, Birch M, Powers R J, Nickerson B G. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia.  J Pediatr. 1994;  124(5 Pt 1) 772-781
• 16 Bhandari V, Bizzarro M J, Shetty A Neonatal Genetics Study Group et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins.  Pediatrics. 2006;  117 1901-1906
• 17 Lavoie P M, Pham C, Jang K L. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health.  Pediatrics. 2008;  122 479-485
• 18 Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Legutko M, Pietrzyk J J. Genetic risk factors of bronchopulmonary dysplasia.  Pediatr Res. 2008;  64 682-688